Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?
Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?
复制标题
DOI：
10.3390/curroncol28050350
复制
发表时间：
2021-10-13
期刊：
影响因子：
--
通讯作者：
Ma K
中科院分区：
文献类型：
--
作者：
Chen X;Ma K
肺癌是最常见、最致命的恶性肿瘤。新辅助治疗是一种有希望的延长生存期和增加治愈率的可能性与潜在的可切除的疾病的患者的方法。目前，包括化疗、靶向治疗和免疫治疗在内的多种治疗方法不断被探索，以丰富新辅助治疗的内容。然而，新辅助治疗至今仍没有统一的评价标准。总生存期（OS）是评价癌症治疗临床获益的“金标准”，但需要数年时间才能进行可靠评估。因此，研究人员需要确定替代终点，可以准确可靠地预测OS，而无需长期随访。本文综述了不同新辅助治疗的研究进展，并探讨其疗效评价，旨在寻找更强的OS预测因子。
Lung cancer is the most fatal and frequently diagnosed malignant tumor. Neoadjuvant therapy is a promising approach for prolonging survival and increasing the chance of cure rates for patients with potentially resectable disease. Currently, many therapeutic alternatives, including chemotherapy, targeted therapy, and immunotherapy, are continually being explored to enrich the content of neoadjuvant therapy. However, neoadjuvant therapy remains to have no unified evaluation standards. Overall survival (OS) is the “gold standard” for evaluating the clinical benefit of cancer treatment, but it needs years for a reliable evaluation. Hence, researchers need to identify surrogate endpoints that can predict OS accurately and reliably without long follow-up periods. In this review, we describe the research progress of different neoadjuvant therapies and explore their response evaluation, aiming to identify stronger predictors of OS.